Overview

Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment

Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
0
Participant gender:
Female
Summary
The purpose of this multi-centre, randomised, double-blind, parallel-group study is to compare efficacy and safety between anastrozole and tamoxifen in pre- and post-operative administration under goserelin acetate treatment for premenopausal breast cancer patients
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AstraZeneca
Treatments:
Anastrozole
Goserelin
Tamoxifen
Criteria
Inclusion Criteria:

- Premenopausal, estrogen receptor positive women, aged 20 years and over, with operable
and measurable breast cancer who have provided written informed consent

Exclusion Criteria:

- Medical history of chemotherapy or endocrine therapy for breast cancer, or with
treatment history of radiotherapy. Unwillingness to stop taking any drug known to
affect sex hormone status (including hormone replacement therapy (HRT).